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Background: Genome variations in human papillomaviruses (HPVs) are common and have been widely
investigated in the past two decades. HPV genotyping depends on the finding of the viral genome variations in the
L1 ORF. Other parts of the viral genome variations have also been implicated as a possible genetic factor in viral
pathogenesis and/or oncogenicity.
Results: In this study, the HPV58 genome in cervical lesions was completely sequenced both by rolling-circle
amplification of total cell DNA and deep sequencing (RCA-seq) and by long PCR template cloning and sequencing.
By comparison of three HPV58 genome sequences decoded from three clinical samples to reference HPV-58, we
demonstrated that RCA-seq is much more accurate than long-PCR template cloning and sequencing in decoding
HPV58 genome. Three HPV58 genomes decoded by RCA-seq displayed a total of 52 nucleotide substitutions from
reference HPV58, which could be verified by long PCR template cloning and sequencing. However, the long PCR
template cloning and sequencing led to additional nucleotide substitutions, insertions, and deletions from an
authentic HPV58 genome in a clinical sample, which vary from one cloned sequence to another. Because the
inherited error-prone nature of Tgo DNA polymerase used in preparation of the long PCR templates of HPV58
genome from the clinical samples, the measurable error rate in incorporation of nucleotide into an elongating DNA
template was about 0.149% ±0.038% in our studies.
Conclusions: Since PCR template cloning and sequencing is widely used in identification of single nucleotide
polymorphism (SNP), our data indicate that a serious caution should be taken in finding of true SNPs in various
genetic studies.
Keywords: Human papillomaviruses, HPV58, Cervical cancer, Single nucleotide polymorphism, Genotyping, Genome
variations, Rolling circle amplification, DNA deep sequencingIntroduction
Human papillomaviruses (HPVs) are a group of more
than 200 genotypes of small DNA tumor viruses
(http://pave.niaid.nih.gov/#home) and can be grouped
clinically as high-risk (oncogenic) types, which are fre-
quently associated with invasive cervical cancer, and
low-risk (non-oncogenic) types, which are found
mainly in genital warts. To date, fifteen HPV types has
been classified as high-risk HPVs, including HPV16,* Correspondence: zhengt@exchange.nih.gov
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[1,2]. Among the high-risk HPVs, HPV16 and HPV18 are
the principal causes of cervical cancer, with a combined,
worldwide contribution to ~70% of invasive cervical cancer
[3,4]. HPV58 has been found to be more prevalent than
HPV18 in cervical intraepithelial neoplasia (CIN) lesions
and appears almost equal frequency as HPV18 in cervical
cancers in Zhejiang province, China [5] and other Asian
countries [6,7]. We recently characterized HPV58 genome
variations and RNA expression in women with cervical le-
sions [8].
HPV genome in size of ~7.9 kb encodes eight open
reading frames (ORFs, E6, E7, E1, E2, E4, E5, L2 and L1)
from one strand of its double stranded, circular genometd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Wang et al. Cell & Bioscience 2014, 4:5 Page 2 of 9
http://www.cellandbioscience.com/content/4/1/5in one direction and a long control region (LCR) between
L1 and E6 [9]. The classification of papillomaviruses by
genotyping depends on the most conserved L1 ORF. A
new type of papillomavirus is granted when its DNA
sequence of L1 ORF differs by more than 10% from the
closest known HPV type. A subtype indicates the differ-
ence between 2% and 10% and a variant represents less
than 2% difference [10-12]. Nucleotide variations in the
LCR region are often used to describe intratype diversity
or variant lineage [12-15]. Despite that HPV genome is
viewed as a stable genome, its genome sequence variations
in a given genotype appear different from one laboratory
to another and from one geological region to another
[14-22]. The reported variations have been found not only
in the L1 ORF and the LCR region, but also in other parts
of the viral genome and were identified mostly, if not
all, by PCR amplicon sequencing. Although it is always
questionable whether an authentic variation (s) does
exist in the reported HPV genotype because of the
use of error-prone Taq polymerase in PCR amplifica-
tion, many attempts have been made to correlate
such genome variations to HPV pathogenesis and
viral carcinogenicity [23-26]. Thus, a more reliable
method is urgently needed to study HPV genome
variation and its possible biological role in HPV in-
fection. Recently, next-generation sequencing (NGS)
techniques are emerging as a promising application
for HPV genotyping and identification of rare single
nucleotide polymorphism (SNP) [8,27-30].
In this report, we analyzed and compared three
HPV58 genome sequences from three cervical lesion
samples decoded by an RCA-seq (rolling-circle amplifi-
cation and deep sequencing) [8,31], a technique that
does not require prior knowledge of the underlying
genome, and by long PCR template cloning and Sanger
sequencing. We demonstrated that RCA-seq is more
reliable method in identification of an authentic nucleo-
tide variation in an episomal viral genome.
Results
To analyze single nucleotide polymorphism (SNP) in
HPV genome, RCA was applied to enrich copy number
of an episomal HPV58 genome from each of three
cervical lesion samples. To quantify HPV58 and host
GAPDH copy numbers from the same sample before
and after RCA, a quantitative real-time PCR (qPCR)
was performed on ~100 pg of sample DNA (samples 10
and 13). The threshold cycle (Ct) values from 2 repeats
were calculated for copy number analysis. Human
GAPDH DNA in linear form served as an internal con-
trol. As expected, we found that RCA enriched HPV58
genome copy number in the sample 13 from 1154 cop-
ies to 7317908 copies (more than 6300-fold enrich-
ment) while displaying no enrichment activity to hostGAPDH linear DNA. The Ct values for GAPDH DNA
were 23.42 before RCA enrichment and 22.76 after
RCA enrichment in the sample 13. A similar result was
observed in the sample 10, in which HPV58 genome
copy was under detection level before RCA, but could
be enriched by RCA to 20481 copies quantified by
qPCR (Figure 1A) and became detectable by agarose gel
electrophoresis (Figure 1B), with only a little enrichment
of host GAPDH linear DNA.
To have the RCA products being deep-sequenced
using an Illumina HiSeq-2000 platform, we subsequently
debranched the RCA products and prepared a paired-end
library from each RCA sample [8,31]. More than 104
millions of paired-end reads from the sample 9, 161
millions from the sample 10, and 120 millions from the
sample 13 were obtained using the RCA-seq. Among
those reads, 3453 in the sample 9, 13249 in the sample
10, and 1.4 million in the sample 13 could be mapped to
the reference HPV58 genome (GI: 222386) [32], giving a
complete coverage of a full-length HPV58 genome [8].
Detailed analyses of the nucleotide sequence at each
position against the reference HPV58 genome [32]
showed that the HPV 58 genomes in three clinical sam-
ples contain nucleotide substitutions being verifiable
either in other samples or in the same sample by the
second RCA-seq [8].
We subsquently cloned the full-length, episomal
HPV58 genome from each clinical sample and compared
each genome sequence obtained by primer-walking
Sanger sequencing to the genome sequence obtained by
the RCA-seq. To do so, the same RCA product from
each clinical sample prepared for RCA-seq, without S1
digestion and DNA shearing, was linearized by AgeI
digestion at nt 62 position or by DraII digestion at nt
4536 position of HPV58 genome. Subsequently, two
large fragments, a ~3.5-kb fragment from nt 3506 to
7036 of HPV58 genome linearized from AgeI-digested
RCA product and a ~4.6-kb fragment from nt 6905 to
3694 of HPV58 genome linearized from DraII-digested
RCA product from each clinical sample, were ampli-
fied separately by high-fidelity thermostable Tgo DNA
polymerase with proofreading activity and inserted
separately into a pCR-XL-TOPO vector. Two clones for
each fragment and four clones for each RCA product of
the individual clinical sample were obtained (Table 1).
All plasmid clones were then sequenced by conventional
primer-walking Sanger sequencing on both strands and the
full-length viral genome sequence was aligned against the
reference HPV58 genome and its corresponding HPV58
genome as determined by RCA-seq.
As shown in Figure 2, 22 nucleotide substitutions in the
sample 9-derived HPV58 (CNZJ-3, GenBank accession
number KC860270), 39 in the sample 10-derived HPV58
(CNZJ-2, GenBank accession number KC860271), and 37
AB
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Figure 1 Enrichment of HPV genomic DNA by RCA from cervical samples. (A) HPV58 genome copy numbers before and after RCA
enrichment. Real-time PCR (qPCR) was performed with an HPV58-specific primer pair on ~100 pg of sample DNA (sample 10 and sample 13)
either before or after RCA enrichment. A 10-fold serial dilution, starting from 100 pg (~1.3 x 107 copies) of the plasmid pXW59-1 which contains
an HPV58 DNA fragment from nt 6906 to 3695 was amplified using the same primer set by qPCR to create a standard curve. The threshold cycle
(Ct) values of qPCR data from 2 repeats were calculated for copy number analysis. GAPDH was used as an internal control. (B) HPV58 DNA in the
sample 10 was under detection level before RCA, but became detectable by agarose gel electrophoresis after enrichment by RCA to 20481 copies
as quantified by qPCR.
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cession number KC860269) found in RCA-seq [8] were all
verified in the HPV58 plasmid clones derived from indi-
vidual clinical samples, but the long PCR template cloning
and sequencing created additional nucleotide variations
to its corresponding viral genome sequence determined
by RCA-seq. The sample 9-derived plasmid sequence-1
(seq-1) decoded from pXHW54-1 plus pXHW57-1 con-
tained additional twelve nucleotide substitutions and four
nucleotide insertions and its seq-2 from pXHW54-2 plus
pXHW57-2 contains five separate nucleotide substitutions,
two separate nucleotide insertions, and one nucleotide dele-
tion (Figure 2 and Table 2). For the sample 10-derived plas-
mid seq-1 decoded from pXHW55-1 plus pXHW58-1 and
the seq-2 from pXHW55-2 plus pXHW58-2, the additional
nucleotide variations include five substitutions, two inser-
tions, and one deletion in its seq-1 and ten separate substi-
tutions in its seq-2 (Figure 2 and Table 2). Similarly, the
viral genome sequence derived from the sample 13 dis-
played additional twelve nucleotide substitutions and two
nucleotide insertions in its seq-1 decoded from pXHW56-1plus pXHW59-1 and nine separate substitutions and one
separate insertion in its seq-2 decoded from pXHW56-2
plus pXHW59-2 (Figure 2 and Table 2). Further analyses of
the additional variations generated by the long PCR tem-
plate cloning and sequencing showed that some of them
could create or inactivate a restriction enzyme cutting site
as summarized in Table 3 and could be therefore verified
by the restriction enzyme digestion. As shown in Figure 3,
AfeI, EcoRV, or FspI could digest the PCR products, re-
spectively, from pXHW57-1, pXHW55-1, or pXHW59-1,
but not the PCR products from their corresponding RCA
preps derived from the same clinical sample, indicating
that these nucleotide variations do not exist in the
authentic HPV58 genome, rather they were most likely
introduced by the long PCR template cloning and
sequencing.
Notably, these additional nucleotide variations from
the long PCR template cloning and sequencing were
random and not duplicable each other between two
cloned viral genome sequences derived from the same
clinical samples. In addition, we found that the insertions
Table 1 The list of plasmids constructed and used in the
study
Plasmid Characteristics
pXHW54 RCA product from HPV58 CNZJ-3 (sample 9) was amplified
with Pr3506 (oYL35) and Pr7036 (oXHW262), gel purified and
cloned into pCR-XL-TOPO vector. Insertion was verified by
sequencing.
pXHW55 RCA product from HPV58 CNZJ-2 (sample 10) was amplified
with Pr3506 (oYL35) and Pr7036 (oXHW262), gel purified and
cloned into pCR-XL-TOPO vector. Insertion was verified by
sequencing.
pXHW56 RCA product from HPV58 CNZJ-1 (sample 13) was amplified
with Pr3506 (oYL35) and Pr7036 (oXHW262), gel purified and
cloned into pCR-XL-TOPO vector. Insertion was verified by
sequencing.
pXHW57 RCA product from HPV58 CNZJ-3 (sample 9) was amplified
with Pr6906 (oXHW263) and Pr3694 (oXHW264), gel purified
and cloned into pCR-XL-TOPO vector. Insertion was verified
by sequencing.
pXHW58 RCA product from HPV58 CNZJ-2 (sample 10) was amplified
with Pr6906 (oXHW263) and Pr3694 (oXHW264), gel purified
and cloned into pCR-XL-TOPO vector. Insertion was verified
by sequencing.
pXHW59 RCA product from HPV58 CNZJ-1 (sample 13) was amplified
with Pr6906 (oXHW263) and Pr3694 (oXHW264), gel purified
and cloned into pCR-XL-TOPO vector. Insertion was verified
by sequencing.
Two bacterial colonies were picked up for each plasmid preparation and the
obtained plasmid preps were named as a plasmid-1 or −2 (such as pXHW54-1
or −2 described in the text).
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fragment always happened at a run of multiple A, T, or C.
Together, a total of additional 70 nucleotide variations
were identified from six cloned HPV58 genome sequences
which differ from the RCA-seq-defined HPV58 genome
sequences. We concluded that these variations were de-
rived from long PCR template amplification with a less ef-
ficient proof-reading Tgo DNA polymerase. By calculation,
the Tgo DNA polymerase exhibited an error rate of
~0.149% ±0.038% in our long PCR template preparation
per HPV58 genome in size of 7824 nts.
Discussion
Rolling-circle amplification (RCA) has been developed
as a powerful tool to amplify a whole genome in an epi-
somal form for microbial genome organization and
phylogenetic analyses [33]. In this study, HPV58 gen-
ome in cervical lesions was decoded, respectively, by
RCA-seq and by long PCR template cloning and se-
quencing. We demonstrated that the RCA-seq is better
than the long PCR template cloning and sequencing in
providing more accurate HPV58 genome sequence.
This conclusion was drawn by comparing the same
genome sequence decoded by the two techniques. All
nucleotide variations to the reference HPV58 genome
identified from each clinical sample by RCA-seq could
be verified by the long PCR template cloning andsequencing, but not vice versa. In addition, the long
PCR template cloning and sequencing technique cre-
ates additional sequence variations, which were ran-
dom and not verifiable from one cloned sequence to
another derived from the same sample.
Although the viral DNA from each clinical sample was
enriched by RCA using phi29 DNA polymerase [34,35]
which features only a minimal error rate of 1 in 106-107
[36] and the reported sequencing accuracy for a NGS
with Illumina HiSeq platform is 98% [37], we found that
RCA-seq in this report displayed a more reliable ap-
proach, by calling consensus bases, in decoding the
entire HPV58 genome in size of 7824 nts. This could be
achieved by using a combination of both high fidelity
phi29 DNA polymerase at the experimental side and ap-
propriate sequencing data analysis at the computational
side. First, we defined a position as identical if more than
95% of the bases obtained were identical to those of the
reference genome. Second, nucleotide substitutions were
identified if the majority of bases in the reads differ from
the reference genome with read depth of 5 or more.
Third, nucleotide positions with read depth less than 5
were treated as ambiguous sites since there is insuffi-
cient depth to make a high confidence call [8].
We determined that additional nucleotide variations ob-
served in our long PCR template cloning and sequencing
were derived from the proofreading error of Tgo DNA
polymerase used in our long PCR template preparation.
Although the enriched DNA chimeras in the RCA reac-
tion which might carry a misincorporated base from
phi29 DNA polymerase amplification were served, after
debranching by AgeI- or DraII-specific digestion of
HPV58 genome, for subsequent long PCR template prep-
aration and cloning, this carry-over possibility appears to
be unlikely because the phi29 DNA polymerase features
only a minimal error rate of 1 in 106-107 [36] in contrast
to ~3 in 104 for PCR with Taq DNA polymerase [38].
Other studies indicate that the majority of DNA sequence
changes introduced during PCR are polymerase-mediated
and PCR accumulates about one mutation per 400 bases
after 30 cycles [38,39]. The PCR-induced transitions are
the major source of error in other NGS studies [40,41].
The reported Tgo DNA polymerase from the Roche prod-
uct manual has an overall error frequency of ~0.2% in nu-
cleotide misincorporation during PCR amplification, very
close to what we found in our study.
In summary, a more accurate RCA-seq superior to PCR
cloning and sequencing has been developed in our lab for
HPV genotyping and determination of SNPs in clinical
HPV variants. Our protocol provides much higher num-
bers of specific HPV reads [8] over other high-throughput
NGS platforms/protocols applied to HPV genotyping
[27-30]. Since PCR sequencing and PCR template cloning
and sequencing are widely used in various epidemiology
NT Ref RCA S1 S2
81 G C C C
388 A C C C
744 T G G G
803 T C C C
1167 T C
1194 T C C C
1453 C T T T






3430 A G G G
3550 T C C C
3587 T G G G
3596 G T T T
3662 T C C C
3940 T C
3978 A C C C
4029 G T T T
4033 C T T T
4621 A C C C
4627 T C C C
4997 T C
5395 G C C C






6560 A G G G





7793 A G G G
Total 22 34 27
Sample 9
NT Ref RCA S1 S2
307 C T T T
667 T A
694 G A A A
744 T G G G
761 G A A A
948 G A A A
1194 T C C C
1360 G C C C
1453 C T T T
1462 A G
1782 C T T T
1895 T C
2289 T C
2340 T C C C
2935 A C C C
3145 T C
3445 C G G G
3550 T C C C
3587 T G G G
3596 G T T T
3824 T C
3949 T C C C
3988 T C C C
4033 C T T T




4627 T C C C
4945 A G G G
5095 T C
5104 A G G G
5119 A G G G
5143 T G G G
5266 G A A A
5378 C T T T
5395 G C C C
5437 A G G G
5489 G A A A
5540 A C C C
6014 A C C C
6074 C T
6275 T C
6416 A G G G
6434 T C C C
6539 A G G G
6560 A G G G
6641 G A A A




7266 C T T T
7714 A G G G
Total 39 44 49
Sample 10
NT Ref RCA S1 S2
307 C T T T
680 A G
694 G A A A
744 T G G G
761 G A A A
948 G A A A
1194 T C C C
1217 A T
1360 G C C C
1453 C T T T
1782 C T T T





2935 A C C C
3245 A G
3445 C G G G
3550 T C C C
3587 T G G G
3596 G T T T
3915 T C
3949 T C C C
3988 T C C C
4033 C T T T
4136 C A A A
4465 T C
4627 T C C C
4735 T C
4885 A G
4945 A G G G
5104 A G G G
5119 A G G G
5143 T G G G
5193 A G
5266 G A A A
5302 T C
5375 A G G G
5395 G C C C
5489 G A A A




6014 A C C C
6287 T C
6330 A G
6416 A G G G
6434 T C C C
6539 A G G G
6641 G A A A
6870 T C
6950 G A A A
6975 T C
7266 C T T T
7714 A G G G
7791 T C
Total 37 49 46
Sample 13
A B C
Figure 2 Nucleotide substitutions identified in HPV58 isolates to the reference HPV58 [32] by RCA-seq and by cloning sequencing.
RCA-seq results were compared to the sequencing results of two individual bacterial clones of each plasmid for samples 9 (A), 10 (B), and 13 (C).
S1 and S2 denotes Sanger sequence #1 (clone #1) and #2 (clone #2), respectively. Common nucleotide substitutions at positions in the reference
HPV58 genome seen from RCA-seq to cloning sequencing were colored in red. The nucleotide substitutions identified only by cloning
sequencing were shown in black.
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should be taken in evaluation of any new SNPs found by
these assays as PCR amplification might introduce nucleo-
tide misincorporation into the studying genotype (s).Materials and methods
Sample DNA preparation
Three HPV58- positive cervical CIN2/3 tissues were
collected from Women's Hospital, School of Medicine,
Table 2 Nucleotide insertion and deletion created by long-PCR amplification in HPV58 isolates
Insertion Deletion
Sample 9 Sample 10 Sample 13 Sample 9 Sample 10 Sample 13










Total 4 2 2 0 2 1 0 1 1 0 0 0
Summarized in this table are nucleotide insertions/deletions introduced by long PCR amplification from the two individual clones in each of three HPV58 isolates.
S1 and S2 denotes Sanger sequence #1 (clone #1) and #2 (clone #2), respectively. Numbers are nucleotide positions in the reference HPV58 genome at where the
insertion or deletion was identified in each HPV58 isolate.
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Institutional Review Board for clinical research of this
hospital. Informed consent was obtained from each par-
ticipant prior the study. DNA was isolated from each
sample by using TRIzol Reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer's instructions.
RCA enrichment, RCA chimeras debranching, paired-end
library preparation and deep sequencing
Rolling circle amplification (RCA) based on phi29 DNA
polymerase used to enrich the HPV58 genome and RCA
chimeras debranching, paired-end library preparation
and deep sequencing with an Illumina HiSeq-2000 plat-
form have described in our other publications [8,31].Table 3 Nucleotide substitutions by long-PCR
amplification in HPV58 isolates create or inactivate
restriction enzyme digestion sites
Sample number
Enzyme nt position* 9 10 13
AfeI 1167 + - -
FspI 2860 - - +
DraIII (inactive) 2925 + - -
FspI 3940 + - -
EcoRV 5095 - + -
BstXI 5556 + - -
MscI (inactive) 6352 + - -
EaeI 6352 + - -
Summarized in this table are distinguishable restriction enzyme cutting sites
due to nucleotide substitutions introduced by long PCR amplification in three
HPV58 isolates. See other details from Figure 3 legends. *The numbers are
nucleotide positions with the substitutions to the reference HPV58 genome.Long PCR template preparation, cloning, and sequencing
RCA products prepared separately from three clinical
samples (sample 9, 10 and 13) without S1 digestion and
DNA shearing were selectively linearized by AgeI or
DraII digestion and then amplified with a primer pair
Pr3506 (5′-GACAGTAGACCACGAGGA-3′, forward) and
Pr7036 (5′-TACTCAGGATC/CGTCCCAAAGGAAACTG
ATC-3′, backward) for AgeI-digested RCA products, and
with a primer pair Pr6906 (5′-TACATCGAATT/CTCCC
AGGCTATTACTTGC-3′, forward) and Pr3694 (5′-CCA
ATGCCATGTGGATGAC-3′, backward) for DraII-digested
RCA products, respectively, using the Expand Long Tem-
plate PCR System (Roche, Cat No. 11681834001). In brief,
2 μl of digested RCA products were used for amplification
in a 50-μl reaction together with 38.75 μl DEPC-treated
water, 2.5 μl dNTP mix (10 mM each)), 0.5 μl of each
forward and reverse primers (20 μM), 5 μL of 10x PCR
buffer II with MgCl2, and 0.75 μl of the expand long
template enzyme mix which contains high-fidelity thermo-
stable Tgo DNA polymerase with proofreading activity. Indi-
vidual long PCR product was gel-purified and cloned into
pCR-XL-TOPO vector according to the manufacturer’s
instruction (Invitrogen, Cat No K4700-10). In brief, the
PCR products generated from AgeI-digested RCA products
using primer pairs Pr3506 (forward) and Pr7036 (backward)
and the PCR products generated from DraII-digested RCA
products using primer pairs Pr6906 (forward) and Pr3694
(backward) were precipitated, purified by agarose gel
electrophoresis using crystal violet and then isolated using
S.N.A.P Gel Purification Kit (Invitrogen). Purified long PCR
products were cloned into a pCR-XL-TOPO vector. Two
clones from each plasmid (Table 1) were prepared and se-
quenced from two different directions. Sequencing results
D ND
RCA p57-1
D ND D ND D ND D ND D ND
RCA p55-1 RCA p59-1
AfeI EcoRV FspI






















Figure 3 Restriction enzyme digestion distinguishes HPV58 amplicons from RCA products to their corresponding plasmids. (A) Diagrams of
HPV58 amplicons from RCA samples and their corresponding plasmid clones with a new restriction enzyme cutting site. (B) Restriction enzyme
digestion of RCA products and their corresponding plasmid clones from each clinical sample. RCA products and pXHW57-1 from the sample 9 were
amplified using a primer pair of Pr743 and Pr1424 and digested with AfeI. RCA products and pXHW55-1 from the sample 10 were amplified using a
primer pair of Pr4974 and Pr5181 and digested with EcoRV. RCA products and pXHW59-1 from the sample 13 were amplified using a primer pair of
Pr2417 and Pr2960 and digested with FspI. The digested products were resolved in 1.5% agarose gel. D: digested; ND: not digested.
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genome to identify nucleotide substitutions, insertions, or
deletions.
Restriction enzyme digestion
RCA product and plasmid pXHW57-1 from the clin-
ical sample 9 were amplified with primer pair Pr743
(5′-CGTGTTGTTACACTTGTGAC-3′) and Pr1424
(5′-GTATTACAACTGTCTACATCCG-3′), and then
digested with AfeI at 37°C overnight. RCA product and
pXHW55-1 from the sample 10 were amplified with
primer pair Pr4974 (5′-CATCTCCTCATAGACTTG
TAAC-3′) and Pr5181 (5′-CGAGTACGAAGTGTAG
CCT-3′), and then digested with EcoRV at 37°C over-
night. RCA product and pXHW59-1 from the sample 13
were amplified with primer pair Pr2417 (5′-GTATGATA
GATGATGTAACAGC-3′) and Pr2960 (5′-ACGCTTTA
GTCTTTGATGCTA-3′), and then digested with FspI
at 37°C overnight. Non-digested products without enzymes
were used as controls.Sequencing data analyses
The trimmed reads were aligned to human (hg19
assembly) from UCSC genome browser and HPV58
reference genome (GenBank accession number D90400
or GI:222386) from PaVe database simultaneously using
the Burrows-Wheeler Alignment tool (BWA) with
default setting [42]. The output alignment files in SAM
format were further processed using SAMtools [43].
The genome coverage files (WIGGLE or BAM files)
were loaded onto the Integrative Genomics Viewer
(IGV, www.broadinstitute.org/igv) to visualize sequence
alignments, genomic annotations and substitutions [44]
with defaulted settings. The cloning sequences were
aligned to HPV58 reference genome using NCBI Blast
tool.
Quantitative real-time PCR
Quantitative real-time PCR, with an HPV58-specific
primer pair Pr 743 (5′-CGTGTTGTTACACTTGTG
AC-3′) and Pr 854 (5′-CTAGGGCACACAATGGTA
Wang et al. Cell & Bioscience 2014, 4:5 Page 8 of 9
http://www.cellandbioscience.com/content/4/1/5CA-3′) using Power SYBR Green PCR Master Mix
(Invitrogen) for high sensitivity and reproducibility, was
performed on ~100 pg of samples DNA (sample #10 and
#13) before and after RCA enrichment, of which the
RCA products from clinical samples #10 and #13 with-
out S1 digestion and DNA shearing were selectively line-
arized by AgeI or DraII digestion. A 10-fold serial
dilution starting from 100 pg (~1.3 x 107 copies) of the
plasmid pXW59 which contains an HPV58 DNA frag-
ment from nt 6906 to 3695 was amplified using the
same primer set by qPCR to create a standard curve.
The threshold cycle (Ct) values of qPCR data from 2 re-
peats were calculated for copy number analysis. A pri-
mer pair optimized for routine SYBR Green real-time
PCR assays which specifically amplifies a genomic
region containing human GAPDH promoter was pur-
chased from Diagenode (Denville, NJ) and was used an
internal control.
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